LONDON, Jan. 29, 2026 /PRNewswire/ -- LifeArc Ventures, the venture capital arm of the medical research organisation, LifeArc, had its most active year to date in 2025, announcing investments in four new innovative life sciences portfolio companies and further funding and supporting its portfolio, which stood at 20 companies at year end. Since its inception in 2020, the portfolio has grown through Seed and Series A investments, expanding its investments into Series B in 2025. LifeArc Ventures participated i ...

Leadership Changes - Kurt von Emster transitions from Head of Abingworth Life Sciences to Managing Partner, focusing on clinical co-development investments and supporting venture investments [1] - Dr. Bali Muralidhar is appointed as the new Head of Abingworth Life Sciences and Chief Investment Officer [1] - Travis Wilson joins as Managing Director, concentrating on clinical co-development and life sciences buyout opportunities [1] Company Background - Abingworth is a leading transatlantic life sciences investment firm and part of Carlyle, having invested in over 185 life science companies since 1973 [3] - The firm has facilitated over 50 mergers and acquisitions and more than 75 IPOs [3] - Abingworth's investments are categorized into seed and early-stage, development stage, and clinical co-development [3] Carlyle Overview - Carlyle is a global investment firm with $474 billion in assets under management as of September 30, 2025 [4] - The firm operates across three business segments: Global Private Equity, Global Credit, and Carlyle AlpInvest [4] - Carlyle employs over 2,400 people in 27 offices worldwide [4]

Company Overview - The Oncology Institute (NASDAQ: TOI) focuses on uniting cancer care practices across the United States to enhance the efficiency of oncological treatments and patient management [1] - The primary objective is to reduce costs associated with cancer care [1] Services Offered - The company provides a range of patient services aimed at improving the overall management of cancer patients [1] Industry Context - The healthcare sector is complex, and financial professionals require scientific and clinical expertise to navigate it effectively [1] - There is a growing need for strategies that bridge the gap between advanced scientific research and financial decision-making in life sciences [1]